ClinicalTrials.gg
CompletedNCT07948291Updated Nov 19, 2026

Timing of Carbetocin Administration in Grand Multiparous Women

A Phase 4 interventional study of Carbetocin in Postpartum Hemorrhage and Grand Multiparity, sponsored by Dr. Lutfi Kirdar Kartal Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Dr. Lutfi Kirdar Kartal Training and Research Hospital · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jan 2025, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 45 studies in Postpartum Hemorrhage with a site in Turkey — 4 open to participants now, 5 under way, none of them phase 3. Postpartum Hemorrhage · Turkey.

Enrollment
15th of 35
172 · median 150
Started
2025
with 6 others
Phase 4
5 of 45
1 open now
Registered
44th of 45
by date

Among the 45 studies in Postpartum Hemorrhage with a site in Turkey, this one is the 15th largest by enrollment of the 35 interventional ones that give a count, is one of 7 that started in 2025, is one of 5 in phase 4, and was the 44th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

4 of the 45 studies in Postpartum Hemorrhage with a site in Turkey are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Postpartum Hemorrhage with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled trial compared two timings of the same prophylactic carbetocin dose in grand multiparous women (five or more previous deliveries) undergoing vaginal delivery. Women received 100 µg intravenous carbetocin either immediately after delivery of the anterior shoulder (before placental delivery) or immediately after complete placental expulsion (after placental delivery). The main question was whether earlier administration reduces postpartum hemorrhage, and whether it affects placental delivery, including the need for manual removal of the placenta.

Read the detailed description

Postpartum hemorrhage (PPH) is a leading cause of maternal morbidity, and uterotonic prophylaxis is central to its prevention. A previous randomized trial in low-risk primiparous women (NCT06776926) showed that pre-placental carbetocin reduced PPH but increased manual placental removal. This single-center, double-blind trial evaluated the same comparison in grand multiparous women with uncomplicated singleton term pregnancies and spontaneous labor.

Allocation was performed by computer-generated simple randomization. A dedicated research midwife not involved in clinical care opened the allocation envelope and prepared and administered the study drug through a peripheral intravenous cannula away from the operative field; participants and the delivering obstetrician were unaware of allocation. Carbetocin (Pabal, Ferring) was given as a single 100 µg (1 mL) intravenous bolus over 1 minute.

Blood loss was measured quantitatively using calibrated under-buttocks collection drapes and gravimetric weighing. Manual removal of the placenta was performed if spontaneous placental delivery had not occurred within 30 minutes after birth.

03

Conditions studied

  • Postpartum Hemorrhage
  • Grand Multiparity

Browse trials for

Keywords

  • Carbetocin
  • Uterotonic Agents
  • Third Stage of Labor
  • Manual Removal of the Placenta
  • Vaginal Delivery
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Grand multiparity (five or more previous deliveries)
  • Age 18-45 years
  • Uncomplicated singleton pregnancy
  • Gestational age of 37 weeks or more
  • Spontaneous onset of labor with vaginal delivery
  • Written

Exclusion criteria

Exclusion Criteria:

  • History associated with increased postpartum hemorrhage risk beyond grand multiparity, including previous placental abruption, uterine rupture, uterine curettage, retained placenta, or peripartum blood transfusion or parenteral iron administration
  • Multifetal pregnancy
  • Fetal macrosomia (estimated fetal weight >4000 g)
  • Polyhydramnios
  • Induction or augmentation of labor with oxytocin
  • Prolonged active phase of labor (>12 hours)
  • >35 kg/m2
  • Hypertensive disorders of pregnancy or preeclampsia
  • Major cardiovascular, hepatic, renal, or endocrine disease
  • Bleeding diathesis, coagulopathy, or use of anticoagulant or antiplatelet agents, including low-dose aspirin
  • Placenta previa or placenta accreta spectrum
  • Known to oxytocin or carbetocin
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    Pre-placental carbetocin

    100 mcg carbetocin administered as an intravenous bolus over 1 minute immediately after delivery of the anterior shoulder, before placental delivery.

    Drug: Carbetocin

  • Active comparator
    Post-placental carbetocin

    100 mcg carbetocin administered as an intravenous bolus over 1 minute immediately after complete placental expulsion.

    Drug: Carbetocin

Interventions

  • DrugCarbetocin

    Single 100 mcg (1 mL) intravenous bolus of carbetocin administered over 1 minute through a peripheral intravenous cannula. Timing of administration differed between arms: immediately after delivery of the anterior shoulder (pre-placental) or immediately after complete placental expulsion (post-placental).

    Also known as: Pabal

06

What researchers measure

Primary outcomes

  1. Incidence of Postpartum Hemorrhage

    Proportion of participants with quantitatively measured blood loss of 500 mL or more, assessed using calibrated under-buttocks collection drapes supplemented by gravimetric weighing.

    Time frame: From delivery of the infant up to 2 hours after delivery

Secondary outcomes

  1. Total Quantitative Blood Loss

    Total peripartum blood loss in milliliters, measured quantitatively using calibrated under-buttocks collection drapes supplemented by gravimetric weighing.

    Time frame: From delivery of the infant up to 2 hours after delivery

  2. Incidence of Severe Postpartum Hemorrhage

    Proportion of participants with quantitatively measured blood loss of 1000 mL or more.

    Time frame: From delivery of the infant up to 2 hours after delivery

  3. Use of Additional Uterotonic Agents

    Proportion of participants requiring additional uterotonic agents (methylergonovine and/or misoprostol).

    Time frame: Within 24 hours after delivery

  4. Manual Removal of the Placenta

    Proportion of participants requiring manual removal of the placenta, performed if spontaneous placental delivery had not occurred within 30 minutes after birth.

    Time frame: From birth of the infant until placental delivery, assessed up to 60 minutes after birth

  5. Duration of the Third Stage of Labor

    Time in minutes from birth of the infant to complete placental expulsion.

    Time frame: From birth of the infant until complete placental expulsion, assessed up to 60 minutes after birth

  6. Transfusion

    Proportion of participants receiving blood transfusion.

    Time frame: Within 24 hours after delivery

  7. Additional Surgical Interventions for Postpartum Hemorrhage

    Proportion of participants requiring additional interventions for postpartum hemorrhage, including intrauterine balloon tamponade, uterine compression sutures, arterial ligation, or hysterectomy.

    Time frame: Within 24 hours after delivery

  8. Antibiotic Administration

    Proportion of participants receiving protocol-driven prophylactic antibiotic administration.

    Time frame: Within 24 hours after delivery

  9. Maternal Adverse Events

    Proportion of participants experiencing adverse events, including nausea, vomiting, dizziness, shivering, headache, dyspnea, flushing, and tachycardia.

    Time frame: Within 24 hours after delivery

  10. Change in Hemoglobin

    Absolute change in hemoglobin (g/dL) from the predelivery value to 24 hours after delivery.

    Time frame: Predelivery (baseline) and 24 hours after delivery

  11. Change in Hematocrit

    Absolute change in hematocrit (percentage points) from the predelivery value to 24 hours after delivery.

    Time frame: Predelivery (baseline) and 24 hours after delivery

07

Study locations

1 site
  • Kartal Dr. Lutfi Kirdar City Hospital
    Istanbul, 34865, Turkey (Türkiye)
08

References and documents

Publications

  • Yildiz P, Keles E, Yildiz G, Kirlangic MM, Dereli ML, Turan K, Elmas A, Mat E. Timing of carbetocin administration in vaginal deliveries: a double-blind, randomized controlled trial. J Perinat Med. 2026 Jun 10;54(7):1127-1133. doi: 10.1515/jpm-2025-0664. Print 2026 Sep 25. PubMed 42286970 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the publication will be available from the corresponding author upon reasonable request.

Time frame: Beginning with publication of the results, with no planned end date.

Access criteria: Data will be shared with qualified researchers upon reasonable request to the corresponding author.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Feb 2025, 1 month.

Of 28 non-industry phase 4 interventional studies under Postpartum Hemorrhage, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 1 month is below that.

Counting every sponsor, half of 29 studies reached it within 12 months; a quarter within 10 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 19, 2026
StartActual
Jan 10, 2025
Primary completionActual
Feb 28, 2025
CompletionActual
Feb 28, 2025
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948291
Lead sponsor
Dr. Lutfi Kirdar Kartal Training and Research Hospital
Responsible party
Cagdas Ozgokce, MD, Assoc. Prof. (Associate Professor of Perinatology, Umraniye Education and Research Hospital) — Principal investigator
First posted
Nov 19, 2026
Start date
Jan 10, 2025
Primary completion
Feb 28, 2025
Completion
Feb 28, 2025
Last update
Nov 19, 2026

Study contacts

Cagdas Ozgokce, MD, Assoc. Prof.
principal investigator · Umraniye Education and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion